FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2149-2151 November 16, 2006 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Scheller, B. PubMed Citation

Percutaneous transluminal coronary angioplasty has become the most frequently used method for myocardial revascularization.¹ The use of uncoated coronary-artery stents during percutaneous intervention has decreased the incidence of acute complications and improved the outcome of patients,² but restenosis within the stent compromises the long-term results. As a consequence, the prevention and treatment of in-stent restenosis have become priorities in interventional cardiology.

Drug-eluting stents, which markedly reduce in-stent restenosis,³ have relegated all other therapeutic approaches to the background. However, it is gradually emerging that rates of late restenosis after the use of drug-eluting stents are higher than initial experience suggested, particularly . . . [Full Text of this Article]

Source Information

From the Cardiology Department, University Hospital, Geneva.

This article was published at www.nejm.org on November 13, 2006.

Related Letters:

Treatment of Restenosis with a Paclitaxel-Coated Balloon Catheter
Sun J. C.J., Eikelboom J. W., Agostoni P., Sangiorgi G. M., Biondi-Zoccai G. G., Scheller B., Böhm M., Camenzind E.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:1071-1073, Mar 8, 2007. Correspondence

This article has been cited by other articles:

• Samady, H., McDaniel, M., Veledar, E., De Bruyne, B., Pijls, N. H., Fearon, W. F., Vaccarino, V. (2009). Baseline Fractional Flow Reserve and Stent Diameter Predict Optimal Post-Stent Fractional Flow Reserve and Major Adverse Cardiac Events After Bare-Metal Stent Deployment. J Am Coll Cardiol Intv 2: 357-363 [Abstract] [Full Text]  
• Takano, M., Yamamoto, M., Murakami, D., Inami, S., Okamatsu, K., Seimiya, K., Ohba, T., Seino, Y., Mizuno, K. (2008). Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent Thrombus: Angioscopic Comparison Between Paclitaxel- and Sirolimus-Eluting Stents. Circ Cardiovasc Interv 1: 20-27 [Abstract] [Full Text]  
• Tharp, D.L., Wamhoff, B.R., Wulff, H., Raman, G., Cheong, A., Bowles, D.K. (2008). Local Delivery of the KCa3.1 Blocker, TRAM-34, Prevents Acute Angioplasty-Induced Coronary Smooth Muscle Phenotypic Modulation and Limits Stenosis. Arterioscler. Thromb. Vasc. Bio. 28: 1084-1089 [Abstract] [Full Text]  
• Agostoni, P., Sangiorgi, G. M., Biondi-Zoccai, G. G.L. (2007). Letter by Agostini et al Regarding Article, "Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern". Circulation 116: e388-e388 [Full Text]  
• Schomig, A., Dibra, A., Windecker, S., Mehilli, J., Suarez de Lezo, J., Kaiser, C., Park, S.-J., Goy, J.-J., Lee, J.-H., Di Lorenzo, E., Wu, J., Juni, P., Pfisterer, M. E., Meier, B., Kastrati, A. (2007). A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. J Am Coll Cardiol 50: 1373-1380 [Abstract] [Full Text]  
• Camenzind, E., Steg, P. G., Wijns, W. (2007). A Cause for Concern. Circulation 115: 1440-1455 [Full Text]  
• Sun, J. C.J., Eikelboom, J. W., Agostoni, P., Sangiorgi, G. M., Biondi-Zoccai, G. G., Scheller, B., Bohm, M., Camenzind, E. (2007). Treatment of Restenosis with a Paclitaxel-Coated Balloon Catheter. NEJM 356: 1071-1073 [Full Text]  
• (2006). Paclitaxel-Coated Balloon Catheter for In-Stent Restenosis?. Journal Watch Cardiology 2006: 2-2 [Full Text]